AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9747404 — intervention group
Group type: COMPARATOR
Intervention: Non-specific counselling
Number of subjects: 74
Study 7882701 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg twice daily
Number of subjects: 81
Study 7882701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 81
Study 7882701 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 81
Study 7882701 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 81
Study 3586503 — intervention group
Group type: COMPARATOR
Intervention: Intravenous deferoxamine (2 g)
Number of subjects: 0
Study 3586503 — intervention group
Group type: COMPARATOR
Intervention: Intravenous deferoxamine (1 g)
Number of subjects: 0
Study 3586503 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular deferoxamine (1 g)
Number of subjects: 0
Study 3586503 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal deferoxamine (2 g)
Number of subjects: 0
Study 3586503 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and intraperitoneal deferoxamine
Number of subjects: 0
Study 30992071 — intervention group
Group type: EXPERIMENTAL
Intervention: Uro-Vaxom®
Number of subjects: 0
Study 30992071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28034064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 482
Study 28034064 — intervention group
Group type: COMPARATOR
Intervention: Three-Dimensional Conformal External Beam Radiation Therapy (3D-CRT)
Number of subjects: 482
Study 28034064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMRT and 3D-CRT
Number of subjects: 482
Study 28034064 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 482
Study 28034064 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 482
Study 26579041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBTp)
Number of subjects: 358
Study 26579041 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 358
Study 23761037 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/d) plus lithium
Number of subjects: 1326
Study 23761037 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/d) plus divalproex
Number of subjects: 1326
Study 23761037 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lithium
Number of subjects: 1326
Study 23761037 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus divalproex
Number of subjects: 1326
Study 21615934 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention based on the Information-Motivation-Behavioural Skills (IMB) Model
Number of subjects: 520
Study 21615934 — intervention group
Group type: COMPARATOR
Intervention: Alcohol use health education leaflet
Number of subjects: 520
Study 19549094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10-40 mg OD)
Number of subjects: 69
Study 19549094 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20-80 mg OD)
Number of subjects: 69
Study 19549094 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg OD)
Number of subjects: 69
Study 19549094 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg OD)
Number of subjects: 69
Study 16672210 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (containing sucrose and caffeine)
Number of subjects: 10
Study 16672210 — intervention group
Group type: COMPARATOR
Intervention: Lemonade
Number of subjects: 10
Study 15233283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide stress
Number of subjects: 12
Study 15233283 — intervention group
Group type: EXPERIMENTAL
Intervention: ARG method with assumed Vd
Number of subjects: 12
Study 15233283 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CBF and change in CBF
Number of subjects: 12
Study 14617265 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler fluxmetry (LDF)
Number of subjects: 14
Study 14617265 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG)
Number of subjects: 14
Study 14617265 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LDF and PPG
Number of subjects: 14
Study 10735790 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg. kg(‐1). min(‐1) continuous infusion)
Number of subjects: 0
Study 10735790 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg bolus followed by placebo continuous infusion)
Number of subjects: 0
Study 10735790 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 10735790 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 8737620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal carbocalcitonin (80 U MRC daily for 12 months)
Number of subjects: 150
Study 8737620 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 150
Study 1591369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cisplatin, decarbazine, carmustine, and tamoxifen
Number of subjects: 0
Study 1591369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 1591369 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological response modifiers (interleukin‐2 and alpha‐interferon)
Number of subjects: 0
Study 3893528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 88
Study 3893528 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 1%
Number of subjects: 88
Study 3893528 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 88
Study 31102644 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sedation
Number of subjects: 585
Study 31102644 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation
Number of subjects: 585
Study 29424335 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (entecavir tablet)
Number of subjects: 0
Study 29424335 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (entecavir tablet)
Number of subjects: 0
Study 27343787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 128
Study 27343787 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 128
Study 24423018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Number of subjects: 40
Study 24423018 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 75 mg twice daily
Number of subjects: 40
Study 23346797 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with secondary and higher education
Number of subjects: 240
Study 23346797 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with primary and vocational education)
Number of subjects: 240
Study 20118030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pegfilgrastim use (all cycles of chemotherapy)
Number of subjects: 0
Study 20118030 — intervention group
Group type: COMPARATOR
Intervention: Reactive pegfilgrastim use (at clinicians' discretion)
Number of subjects: 0
Study 18687421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 1851
Study 18687421 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (waitlist vs. psychological control)
Number of subjects: 1851
Study 15833779 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90
Study 15833779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 15833779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study 12457662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zyoptix wavefront-guided LASIK
Number of subjects: 12
Study 12457662 — intervention group
Group type: COMPARATOR
Intervention: PlanoScan LASIK
Number of subjects: 12
Study 10404713 — intervention group
Group type: EXPERIMENTAL
Intervention: Single item visual analogue scales (VASs) for irritability, tension, depression, and mood swings; Premenstrual Tension Syndrome Observer (PMTS‐O) and Self‐Rating (PMTS‐SR) scales
Number of subjects: 0
Study 7675608 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective condition (model observed from the rear)
Number of subjects: 30
Study 7675608 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking-glass condition (model facing the subject, viewing performance opposite directions)
Number of subjects: 30
Study 7675608 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective condition (model facing the subject)
Number of subjects: 30
Study 7675608 — intervention group
Group type: COMPARATOR
Intervention: Retention across all conditions
Number of subjects: 30
Study 2200296 — intervention group
Group type: EXPERIMENTAL
Intervention: Anjuvac (modified alginate conjugated birch pollen extract)
Number of subjects: 63
Study 2200296 — intervention group
Group type: COMPARATOR
Intervention: Alutard (aluminium adsorbed birch pollen extract)
Number of subjects: 63
Study 7021266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac 5% cream
Number of subjects: 0
Study 7021266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31260794 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-driven recommendation of restricted fluid intake, diuretics, and ultrafiltration initiated from 48 hours up to 14 days after admission.
Number of subjects: 1440
Study 31260794 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1440
Study 28782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Methodology (ESM)
Number of subjects: 100
Study 26187183 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by community health workers using an Android app, focusing on medication use and lifestyle modifications.
Number of subjects: 2086
Study 26187183 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by community health workers using an Android app.
Number of subjects: 2086
Study 24172699 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus alpha-lipoic acid 300 mg twice daily
Number of subjects: 30
Study 24172699 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 30
Study 21645507 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg twice a day (titrated to 10 μg twice a day after 1 month)
Number of subjects: 111
Study 21645507 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 mg three times a day (titrated to 2 mg three times a day after 1 month)
Number of subjects: 111
Study 19468259 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (SDMI)
Number of subjects: 220
Study 19468259 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure to reach a treatment agreement (control)
Number of subjects: 220
Study 16433641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 56
Study 16433641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15232804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% added to cardioplegia solution
Number of subjects: 21
Study 15232804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sevoflurane)
Number of subjects: 21
Study 11389784 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen or hormone replacement therapy (ERT or HRT)
Number of subjects: 0
Study 11389784 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9517609 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 84 microg twice a day
Number of subjects: 15
Study 9517609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8044121 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 8044121 — intervention group
Group type: COMPARATOR
Intervention: Advice
Number of subjects: 0
Study 3191663 — intervention group
Group type: COMPARATOR
Intervention: Timolol (non-selective beta-blocker, 10 mg b.i.d. for 5 days)
Number of subjects: 21
Study 3191663 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective beta-blocker, 100 mg b.i.d. for 5 days)
Number of subjects: 21
Study 3191663 — intervention group
Group type: COMPARATOR
Intervention: Timolol (non-selective beta-blocker)
Number of subjects: 21
Study 3191663 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective beta-blocker)
Number of subjects: 21
Study 3191663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beta-blockers
Number of subjects: 21
Study 19546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row suture anchor repair
Number of subjects: 8
Study 19546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row suture bridge repair
Number of subjects: 8
Study 761001 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 761001 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 30529466 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of abnormal PTE bone signal and/or erosion
Number of subjects: 961
Study 30529466 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PTE abnormalities
Number of subjects: 961
Study 30529466 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PTE abnormalities
Number of subjects: 961
Study 30283184 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg loading dose over 15 min, followed by 10 mg/kg/h for 1 h)
Number of subjects: 60
Study 30283184 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (10 mg/kg infusion started with induction and continued for 1 h)
Number of subjects: 60
Study 30283184 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 60
Study 30283184 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 60
Study 26890200 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc, selenium, glutamine, and metoclopramide
Number of subjects: 229
Study 26890200 — intervention group
Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 229
Study 25407227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of olive oil for cooking, an olive oil based spread, and a daily supplement drink enriched with Vitamin D (10 microgram daily) and marine omega‐3 fatty acids (2 g daily) for 6 weeks preconception
Number of subjects: 110
Study 25407227 — intervention group
Group type: COMPARATOR
Intervention: Control diet of sunflower seed oil for cooking, a sunflower oil based spread, and a daily supplement drink without added Vitamin D or marine omega‐3 fatty acids
Number of subjects: 110
Study 22957013 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment at a dose of 50 IU/kg/week for 3 injections over 18 days
Number of subjects: 18
Study 22957013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPO treatment)
Number of subjects: 18
Study 19440168 — intervention group
Group type: EXPERIMENTAL
Intervention: Discoblock (intradisc injection of 0.75 mL of 0.5% bupivacaine)
Number of subjects: 42
Study 19440168 — intervention group
Group type: COMPARATOR
Intervention: Discography (1.5 mL of contrast medium)
Number of subjects: 42
Study 19440168 — intervention group
Group type: EXPERIMENTAL
Intervention: Discoblock
Number of subjects: 42
Study 19440168 — intervention group
Group type: COMPARATOR
Intervention: Discography
Number of subjects: 42
Study 17487928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (cranberry-OAC, n = 89)
Number of subjects: 177
Study 17487928 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (placebo-OAC, n = 88)
Number of subjects: 177
Study 17487928 — intervention group
Group type: COMPARATOR
Intervention: OAC alone (non-placebo-OAC, n = 712)
Number of subjects: 177
Study 12701864 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE with single-drop instillation of mitomycin C (MMC) 0.02% at the end of the surgery
Number of subjects: 80
Study 12701864 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE with postoperative MMC 0.02% drops twice a day for 5 days
Number of subjects: 80
Study 12701864 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE with intraoperative MMC 0.02%
Number of subjects: 80
Study 12701864 — intervention group
Group type: COMPARATOR
Intervention: Bare scleral excision (BSE)
Number of subjects: 80
Study 10880548 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Menopausal Assessment (CMA) intervention program
Number of subjects: 76
Study 10880548 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 76
Study 8818848 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 530
Study 8818848 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily for 10 days
Number of subjects: 530
Study 8818848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 530
Study 1373360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg/day)
Number of subjects: 32
Study 1373360 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 32
Study 3904392 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 74
Study 3904392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31162592 — intervention group
Group type: EXPERIMENTAL
Intervention: Photovoice exercise in diabetes self-management education program
Number of subjects: 37
Study 26002873 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Violence Prevention Treatment (IVPT)
Number of subjects: 0
Study 26002873 — intervention group
Group type: COMPARATOR
Intervention: Control condition (anger management session and psycho-educational sessions)
Number of subjects: 0
Study 25818976 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoperistaltic stapled side-to-side anastomosis (SSSA)
Number of subjects: 40
Study 25818976 — intervention group
Group type: COMPARATOR
Intervention: Antiperistaltic stapled side-to-side anastomosis (SSSA)
Number of subjects: 40
Study 25818976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 22868247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent LHRH therapy
Number of subjects: 31
Study 22868247 — intervention group
Group type: COMPARATOR
Intervention: Continuous LHRH therapy
Number of subjects: 31
Study 21209062 — intervention group
Group type: EXPERIMENTAL
Intervention: Scorpion antivenom plus prazosin
Number of subjects: 70
Study 21209062 — intervention group
Group type: COMPARATOR
Intervention: Prazosin alone
Number of subjects: 70
Study 19684500 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment for 12 sessions (5 sessions per week)
Number of subjects: 19
Study 19684500 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 19
Study 17373863 — intervention group
Group type: EXPERIMENTAL
Intervention: First ONS (oral nutritional supplement)
Number of subjects: 32
Study 17373863 — intervention group
Group type: EXPERIMENTAL
Intervention: Second ONS
Number of subjects: 32
Study 17373863 — intervention group
Group type: EXPERIMENTAL
Intervention: Third ONS
Number of subjects: 32
Study 15220011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 398
Study 15220011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 398
Study 11288158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (n = 40)
Number of subjects: 84
Study 11288158 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (n = 44)
Number of subjects: 84
Study 9404990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured allogeneic keratinocyte sheets
Number of subjects: 0
Study 9404990 — intervention group
Group type: COMPARATOR
Intervention: Op-Site treatment
Number of subjects: 0
Study 7506159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg twice daily
Number of subjects: 68
Study 7506159 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500mg twice daily
Number of subjects: 68
Study 3711534 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral dipyridamole
Number of subjects: 50
Study 3711534 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dipyridamole
Number of subjects: 50
Study 3711534 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral dipyridamole
Number of subjects: 50
Study 3711534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (200 or 400 mg)
Number of subjects: 50
Study 31729600 — intervention group
Group type: EXPERIMENTAL
Intervention: R,S‐1,3‐butanediol (BD) 0.35 g kg‐1
Number of subjects: 9
Study 31729600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31258919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 µg (VI)
Number of subjects: 1673
Study 31258919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 µg (FF)
Number of subjects: 1673
Study 31258919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vilanterol 25 µg and Fluticasone furoate 100 µg (VI 25/FF 100)
Number of subjects: 1673
Study 31258919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1673
Study 29211225 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 630
Study 29211225 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 630
Study 26374696 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min breathing retraining plus education
Number of subjects: 33
Study 26374696 — intervention group
Group type: COMPARATOR
Intervention: 20-min standard education
Number of subjects: 33
Study 23937597 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (≥5.5% Δ⁹‐tetrahydrocannabinol/THC)
Number of subjects: 18
Study 23937597 — intervention group
Group type: COMPARATOR
Intervention: Inactive marijuana (0.0% THC)
Number of subjects: 18
Study 21766559 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A or beta-carotene supplementation (placebo-controlled)
Number of subjects: 1435